Early intervention and continuous treatment in schizophrenia are key to ensuring good outcomes. This includes determining patient’s treatment goals, developing a relapse prevention plan, and acknowledging adherence issues, but is there a role for long-acting injectable antipsychotics (LAIs)? The case was put forward in this ECNP2020 Satellite symposium.
Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.
